Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK1 | Q13464 | 18/20 | 0.54 |
| ▸ | GRK2 | P25098 | 16/20 | 0.54 |
| ▸ | GRK5 | P34947 | 12/20 | 0.54 |
| ▸ | RPS6KB1 | P23443 | 5/20 | 0.54 |
| ▸ | RPS6KA1 | Q15418 | 5/20 | 0.54 |
| ▸ | GRK1 | Q15835 | 6/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2567568 | 0.78 | GRK2 (0.80) | ROCK1GRK2GRK5RPS6KB1RPS6KA1 | |
| SCHEMBL2565505 | 0.77 | GRK2 (0.82) | ROCK1GRK2GRK5RPS6KB1RPS6KA1 | |
| SCHEMBL2565978 | 0.76 | GRK2 (0.71) | ROCK1GRK2GRK5RPS6KB1RPS6KA1 | |
| SCHEMBL12162716 | 0.74 | GRK2 (0.63) | ROCK1GRK2GRK5RPS6KB1RPS6KA1 | |
| SCHEMBL2567360 | 0.74 | GRK2 (0.63) | ROCK1GRK2GRK5RPS6KB1RPS6KA1 | |
| SCHEMBL2566824 | 0.74 | GRK2 (0.63) | ROCK1GRK2GRK5RPS6KB1RPS6KA1 | |
| SCHEMBL2570905 | 0.74 | GRK2 (0.68) | ROCK1GRK2GRK5RPS6KB1RPS6KA1 | |
| SCHEMBL2566490 | 0.74 | ROCK1 (0.70) | ROCK1GRK2GRK5RPS6KB1RPS6KA1 | |
| SCHEMBL2565919 | 0.74 | ROCK1 (0.58) | ROCK1GRK2GRK5RPS6KB1RPS6KA1 | |
| SCHEMBL2565917 | 0.74 | ROCK1 (0.58) | ROCK1GRK2GRK5RPS6KB1RPS6KA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7560467-B2 | Indazolo-tetrahydropyrimidine-carboxamide derivative kinase inhibitors | SMITHKLINE BEECHAM CORPORATION (US) | 2009-07-14 | — | — | US | disclosed |
| US-20070099944-A1 | Chemical compounds | SMITHKLINE BEECHAM CORPORATION | 2007-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070099944-A1 | Chemical compounds | ROCK1, ROCK2, CIT | ROCK1 1/4885GRK2 165/4885GRK5 68/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.